-
Media Release
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
-
Media Release
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
-
Media Release
Novartis peer-reviewed safety and tolerability data further strengthens Kesimpta’s (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosis
-
Story
Toward regrowing cartilage -
Story
Turning research advances into innovative medicines